10-Q: Tivic Health Pivots to Biopharma Amidst Mounting Losses

Tivic Health Systems, Inc. reported increased net losses and negative cash flow for Q3 2025, accelerating its pivot from consumer health to biopharmaceutical development while facing going concern doubts and manufacturing delays.

Summary

• Tivic Health Systems, Inc. is transitioning from a consumer healthtech company (ClearUP) to a late-stage prescription therapeutics company focused on biopharmaceuticals.
• The company incurred a net loss of $6.0 million for the nine months ended September 30, 2025, compared to $4.2 million for the same period in 2024.
• Revenue decreased by 50% to $302 thousand for the nine months ended September 30, 2025, from $600 thousand in the prior year, primarily due to reduced advertising for ClearUP.
• Gross profit turned into a loss of $41 thousand for the nine months ended September 30, 2025, down from a profit of $241 thousand in 2024, largely due to a $230 thousand inventory reserve for excess and obsolete ClearUP inventory.
• Operating expenses increased by $1.46 million to $5.88 million for the nine months ended September 30, 2025, driven by increased research and development costs for the biopharma program.
• Cash and cash equivalents increased to $3.45 million at September 30, 2025, from $2.00 million at December 31, 2024, primarily due to financing activities.
• The company had negative cash flows from operations of $4.7 million for the nine months ended September 30, 2025.
• A 1-for-17 reverse stock split was implemented on March 7, 2025.
• The company acquired an exclusive worldwide license for Entolimod for Acute Radiation Syndrome (ARS) and an option for neutropenia, which was exercised in March 2025.
• Scorpius BioManufacturing, Inc. was engaged as the primary U.S. manufacturer for Entolimod, with an estimated investment of $4.1 million over two years.
• The company raised capital through an Equity Line of Credit with Mast Hill Fund, L.P. (up to $25 million) and a Tranched Financing with an investor (up to $8.4 million), completing four tranches for $4.9 million gross proceeds.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, including increased net losses, negative gross profit, and a going concern warning. The wind-down of its only revenue-generating product (ClearUP) means zero revenue until new biopharma products are approved, which is a long and uncertain path. Manufacturing delays and government shutdown impacts further complicate the outlook. However, the successful capital raises and the strategic pivot into biopharma with FDA Fast Track/Orphan Drug designations for Entolimod represent a high-risk, high-reward strategy that could yield significant value if successful. The sentiment is low due to immediate financial and operational headwinds, but not entirely negative due to the potential of the new pipeline and recent funding.

Positives

• Successful acquisition of exclusive worldwide license for Entolimod for Acute Radiation Syndrome (ARS) and neutropenia, marking a strategic pivot into the biopharmaceutical market.
• Entolimod has received FDA Fast Track and Orphan Drug designations for ARS treatment, which can accelerate development and review.
• Completion of four tranches of the Preferred Purchase Agreement, raising aggregate gross proceeds of $4.9 million and net proceeds of $4.3 million, improving cash position to $3.45 million.
• Successful completion of an optimization study for the non-invasive vagus nerve stimulation (ncVNS) device, with positive outcomes and resulting in additional intellectual property filings.
• Net loss per share improved to $(6.54) for the nine months ended September 30, 2025, compared to $(18.22) in the prior year, despite an increase in total net loss, due to a higher weighted-average share count.
• Strategic hires, including a Chief Operating Officer/President of Tivic Biopharma and a Chief Financial Officer, to support the new biopharma focus.

Negatives

• Significant increase in net loss to $6.0 million for the nine months ended September 30, 2025, from $4.2 million in the prior year.
• Gross profit turned into a loss of $41 thousand for the nine months ended September 30, 2025, compared to a profit of $241 thousand in 2024, primarily due to a $230 thousand inventory reserve for obsolete ClearUP inventory.
• Revenue from ClearUP decreased by 50% to $302 thousand for the nine months ended September 30, 2025, as the company winds down this business.
• Negative cash flows from operations increased to $4.7 million for the nine months ended September 30, 2025, from $4.4 million in the prior year.
• The company has an accumulated deficit of $49.6 million as of September 30, 2025.
• A material weakness in internal controls over financial reporting was identified as of December 31, 2024, due to the small size of the accounting and financial reporting team.
• The contract manufacturer for Entolimod, Scorpius BioManufacturing, Inc., is experiencing financial stress, leading to delays in the clinical development timeline and potential additional costs.
• The wind-down of the ClearUP business incurred $347 thousand in charges during Q3 2025, with additional expenditures of $20 thousand to $50 thousand expected by year-end.
• The U.S. federal government shutdown (October 1 November 12, 2025) delayed SEC review of registration statements, impacting the timing of the fifth and sixth tranches of the Preferred Purchase Agreement.

Risks

• Substantial doubt about the company's ability to continue as a going concern within one year due to significant expenses, operating losses, and negative cash flows.
• Requires substantial additional financing to fund ongoing clinical trials, operations, and strategic expansion; no assurance that financing will be available on acceptable terms.
• No assurance of obtaining regulatory approval for product candidates or generating sufficient revenue to achieve profitability.
• The wind down of the ClearUP business may adversely impact business, results of operations, financial performance, and reputation; costs may exceed estimates, and anticipated benefits may not be realized.
• Reliance on third-party providers for the supply and manufacturing of product candidates (e.g., Scorpius) could lead to supply shortages, delays, increased costs, or cessation of production, especially given Scorpius's financial stress.
• Prolonged U.S. federal government shutdowns can delay regulatory approvals (FDA), SEC filings, and access to capital markets, materially affecting business and financing activities.
• Ongoing conflicts (Russia-Ukraine, Israel-Hamas), tariffs, inflation, rising interest rates, and economic uncertainty contribute to volatility and could negatively affect operations and capital markets.
• Potential for supply shortages for Entolimod due to contract manufacturer's financial instability and general global supply chain constraints.
• Manufacturing of biologics is inherently unpredictable, and costs and timelines associated with development of the manufacturing processes may vary materially from expectations.
• Clinical and preclinical development timelines, the probability of success, and costs can differ materially from expectations.
• Costs involved in prosecuting and enforcing patent and other intellectual property claims.
• Competing technological and market developments.
• Sale of additional equity would result in additional dilution to stockholders.
• Incurrence of additional debt would result in debt service obligations and restrictive covenants.
• Raising funds through collaborations or partnerships may require relinquishing valuable rights to technologies or revenue streams.
• If adequate funds are not available, the company may be forced to reduce spending, reprioritize investments, extend payment terms, liquidate assets, or suspend/curtail planned programs.
• A material weakness in internal controls over financial reporting due to the small accounting and financial reporting team poses a risk of material misstatement not being prevented or detected timely.
• Geopolitical issues, inflation, interest rate changes, and business shifts make it difficult to accurately forecast future revenues or financial results.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future as it develops and seeks regulatory approval for its biopharmaceutical product candidates (Entolimod, Entolasta) and technologies. Revenue from the ClearUP consumer business is expected to decrease significantly and eventually cease by year-end 2025, with minimal to no revenue generated until regulatory approval and commercialization of new product candidates. Investments in the bioelectronics program (VNS) may be significantly reduced or eliminated as resources are focused on the lead biopharma candidate, Entolimod. The company will require substantial additional financing to fund operations and execute its strategy, with no assurance of availability on commercially acceptable terms.

Management Comments

• "We expect to incur significant expenses and operating losses for the foreseeable future as we continue the development of, and seek regulatory approval for, our product candidates and technologies."
• "We will require substantial additional financing to fund our ongoing clinical trials and operations, and to continue to execute our strategy."
• "There can be no assurance that we will obtain regulatory approval of our product candidates or generate sufficient revenue and cash to achieve profitability."
• "Our immediate focus with Entolimod will be validation of the manufacturing process sufficient to submit a biologics license application (BLA) to the FDA."
• "We believe these properties have the potential to make our TLR5 agonists compelling as adjuvants and/or as alternatives to currently marketed G-CSF."
• "While study outcomes have been positive, the company is currently focusing its resources on the advancement of its lead product candidate and investments in its bioelectronics program may be significantly reduced or eliminated."
• "We have continued to intentionally maintain a small core team at this stage of the Company, including managing our headcount to reduce operating expenses; however, as we progress in the clinical development of our product candidates, we expect that we will increase our headcount to address our needs."
• "We expect revenues to decrease significantly as we plan to exit the consumer business by the end of the year."
• "We are no longer spending the significant advertising and marketing costs required to support sales of ClearUP."
• "Our near-term focus is to advance the development of our biopharmaceutical product candidates and to ultimately obtain regulatory approval of our product candidates and generate revenue through the sale thereof."
• "We expect that our operating expenses may increase significantly as we discover, acquire, validate and develop our current product candidates and new product candidates; seek regulatory approval and, if approved, proceed to commercialization of new products..."
• "We expect to reduce our costs for advertising and marketing of ClearUP as we wind down our consumer health business and shift our capital resources to the advancement of our TLR5 agonist programs."
• "Although we have explored alternative monetization strategies for ClearUP, our efforts have been unsuccessful and we have determined to move forward with the wind down of our consumer health business."
• "We are continuing to monitor their situation and are considering our options [regarding Scorpius's financial stress]."

Industry Context

Tivic Health is undergoing a significant strategic pivot, exiting the competitive consumer healthtech market (ClearUP) to focus on the high-risk, high-reward biopharmaceutical sector, specifically in immune system modulation (TLR5 agonists for ARS and neutropenia) and bioelectronic medicine (VNS). This shift aligns with a broader trend in healthcare towards specialized, evidence-based therapeutics and away from consumer-facing devices for general wellness, especially for companies struggling with profitability in the latter. The biopharma space, while offering substantial upside if successful, demands significant capital investment, faces lengthy regulatory pathways, and carries high clinical trial failure rates. The company's focus on ARS and neutropenia addresses critical unmet medical needs, potentially attracting government funding or partnerships, as evidenced by Entolimod's prior Department of Defense investment and FDA designations. However, the reliance on third-party manufacturers and the financial distress of its primary contract manufacturer highlight the supply chain vulnerabilities common in the specialized biomanufacturing industry. The VNS program, while showing positive early results, is being de-prioritized, reflecting the intense capital allocation decisions required during such a transition.

Comparison to Industry Standards

• Entolimod has received FDA Fast Track and Orphan Drug designations for ARS, which are positive indicators for a drug candidate addressing an unmet need, comparable to other biopharma companies developing treatments for rare or critical conditions.
• Prior investment in Entolimod, including $35.6 million from government agencies (Department of Defense, NASA, NIH), indicates significant external validation and funding for its potential, a strong signal for a late-stage asset.
• The mechanism of action for Entolimod and Entolasta, activating the NF-kappaB pathway upstream of G-CSF and showing anti-apoptotic benefits, suggests a potentially differentiated profile compared to existing G-CSF drugs like Neupogen or Neulasta, which primarily stimulate neutrophil production.
• The company's ncVNS approach, with positive pilot and optimization study outcomes from the Feinstein Institutes for Medical Research at Northwell Health, suggests potential for clinical utility in areas like PTSD, cardiac disease, inflammatory conditions, and ischemic stroke, positioning it within a growing field of bioelectronic medicine with competitors like LivaNova and electroCore.
• The company's current financial state, with increasing net losses, negative gross profit, and a going concern warning, is below industry standards for established, profitable companies, but initial losses and capital raises are common for companies undergoing a significant pivot into high-cost drug development.

Management Changes

Corporate Governance

Legal Proceedings

• No current legal proceedings, litigation, or claims that would have a material adverse effect.

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders face significant dilution from recent and planned equity raises. Increased risk due to going concern warning and pivot to high-risk biopharma, with potential for long-term value if the biopharma pipeline succeeds, but high near-term volatility and risk of loss.
• Employees may experience job reallocations or reductions in the consumer health division due to the strategic shift and wind-down of ClearUP, while new hires are being made for the biopharma segment.
• Customers of ClearUP will be impacted by the discontinuation of the product, though resellers may continue sales until inventory is depleted.
• Suppliers and manufacturers face dependency and risk, especially with the financial distress of key contract manufacturer Scorpius, and new supplier relationships will be needed for the biopharma program.
• Creditors face increased risk due to the going concern warning and the company's ongoing need for additional financing.

Next Steps

• Substantially complete the wind down of the ClearUP business prior to the end of 2025.
• Incur additional expenditures related to the ClearUP wind-down in the range of approximately $20 thousand to $50 thousand through the end of 2025.
• Advance the development of biopharmaceutical product candidates (Entolimod, Entolasta).
• Validate the manufacturing process for Entolimod sufficient to submit a Biologics License Application (BLA) to the FDA.
• Initiate one or more Phase 2 clinical studies for Entolimod and/or Entolasta for the treatment of neutropenia and other oncology-related indications.
• Monitor the financial situation of Scorpius BioManufacturing, Inc. and consider options for alternative contract manufacturers.
• Increase headcount as clinical development of product candidates progresses.
• Implement compliance programs related to potential government customers.
• Raise additional capital to fund ongoing clinical trials and operations.
• Regularly evaluate alternative and secondary manufacturing partners and source suppliers.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Complete the fifth and sixth Tranche Closings of the Preferred Purchase Agreement (subject to conditions).

Key Dates

Recommendation

The company is in a highly precarious financial position, explicitly stating "substantial doubt about the Company's ability to continue as a going concern within one year." It is winding down its only revenue-generating product, ClearUP, leading to an expected cessation of revenue until new biopharma products are approved, a process that is lengthy, costly, and uncertain. The company reported increased net losses and negative gross profit, alongside growing operating expenses. While capital has been raised, it is insufficient for long-term needs, and further dilution is expected. Operational delays with its key biopharma manufacturer and impacts from government shutdowns add to the significant risks. The strategic pivot to biopharma is high-risk, and the immediate financial outlook is extremely challenging, making the stock a strong sell for investors.

Keywords

Biopharmaceutical, Acute Radiation Syndrome, Neutropenia, Entolimod, TLR5 agonist, Vagus Nerve Stimulation, Bioelectronic Medicine, ClearUP, SEC 10-Q, Going Concern, Capital Raise, Clinical Trials, FDA Fast Track, Orphan Drug, Manufacturing Delays, Reverse Stock Split, Nasdaq